Literature DB >> 21531161

Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis.

Ignacio J Posada, Ana Ramos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21531161     DOI： 10.1016/j.parkreldis.2011.04.006

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN： 1353-8020            Impact factor:   4.891


× No keyword cloud information.
  4 in total

1.  Leukodystrophy with a cerebellar cystic aspect and intracranial atherosclerosis: an atypical presentation of cerebrotendinous xanthomatosis.

Authors:  Géraldine Androdias; Sandra Vukusic; Laurence Gignoux; Odile Boespflug-Tanguy; Cécile Acquaviva; Marie-Thérèse Zabot; Philippe Couvert; Alain Carrie; Christian Confavreux; Pierre Labauge
Journal:  J Neurol       Date:  2011-07-19       Impact factor: 4.849

Review 2.  Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders.

Authors:  Melissa D Svoboda; Jill M Christie; Yasemen Eroglu; Kurt A Freeman; Robert D Steiner
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-10-05       Impact factor: 3.908

Review 3.  Natural history of neurological abnormalities in cerebrotendinous xanthomatosis.

Authors:  Janice C Wong; Kailey Walsh; Douglas Hayden; Florian S Eichler
Journal:  J Inherit Metab Dis       Date:  2018-02-26       Impact factor: 4.982

4.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.